RISK OF HYPERKALEMIA ASSOCIATED WITH THE USE OF BLOCKERS OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN THE TREATMENT OF HEART FAILURE: A REVIEW

Gabriela da Silveira Aguiar, Zilma Barreto, C. Cruz
{"title":"RISK OF HYPERKALEMIA ASSOCIATED WITH THE USE OF BLOCKERS OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN THE TREATMENT OF HEART FAILURE: A REVIEW","authors":"Gabriela da Silveira Aguiar, Zilma Barreto, C. Cruz","doi":"10.17267/2317-3386bjmhh.v1i2.238","DOIUrl":null,"url":null,"abstract":"Heart failure (HF) is the leading cause of hospitalizations for cardiovascular diseases in Brazil. Hyperkalemia is an important adverse effect of therapy for HF. Several factors affect the incidence of hyperkalemia in patients treated for HF, as well as the presence of comorbidities and the use of  associated  medications. The aim of this study is to gather new evidence regarding the risk of hyperkalemia in patients treated for HF. The well-established therapy for HF involves drugs that may lead to hyperkalemia as inhibitors of angiotensin converting enzyme blockers, angiotensin II receptor blockers, aldosterone receptor blockers and direct renin inhibitors. The high incidence of HF in elderly patients with comorbidities such as diabetes mellitus and renal insufficiency increases the risk of hyperkalemia. Anti-inflammatory drugs, trimethoprim-sulfamethoxazole and heparin may aggravate the situation. Conclusion: Given the risk of hyperkalemia in patients undergoing treatment for HF, cautious monitoring of renal function and serum potassium should be performed.","PeriodicalId":280405,"journal":{"name":"Brazilian Journal of Medicine and Human Health","volume":"14 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2013-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brazilian Journal of Medicine and Human Health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17267/2317-3386bjmhh.v1i2.238","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Heart failure (HF) is the leading cause of hospitalizations for cardiovascular diseases in Brazil. Hyperkalemia is an important adverse effect of therapy for HF. Several factors affect the incidence of hyperkalemia in patients treated for HF, as well as the presence of comorbidities and the use of  associated  medications. The aim of this study is to gather new evidence regarding the risk of hyperkalemia in patients treated for HF. The well-established therapy for HF involves drugs that may lead to hyperkalemia as inhibitors of angiotensin converting enzyme blockers, angiotensin II receptor blockers, aldosterone receptor blockers and direct renin inhibitors. The high incidence of HF in elderly patients with comorbidities such as diabetes mellitus and renal insufficiency increases the risk of hyperkalemia. Anti-inflammatory drugs, trimethoprim-sulfamethoxazole and heparin may aggravate the situation. Conclusion: Given the risk of hyperkalemia in patients undergoing treatment for HF, cautious monitoring of renal function and serum potassium should be performed.
高钾血症的风险与使用肾素-血管紧张素-醛固酮系统阻滞剂治疗心力衰竭相关:综述
心力衰竭(HF)是巴西心血管疾病住院的主要原因。高钾血症是心衰治疗的一个重要不良反应。几个因素影响HF患者高钾血症的发生率,以及合并症的存在和相关药物的使用。本研究的目的是收集关于心衰患者高钾血症风险的新证据。心衰的成熟治疗包括可能导致高钾血症的药物,如血管紧张素转换酶阻滞剂、血管紧张素II受体阻滞剂、醛固酮受体阻滞剂和直接肾素抑制剂。合并糖尿病、肾功能不全等合并症的老年心衰患者的高发增加了高钾血症的风险。消炎药、甲氧苄啶-磺胺甲恶唑和肝素可能会加重这种情况。结论:考虑到接受HF治疗的患者存在高钾血症的风险,应谨慎监测肾功能和血钾。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信